Telogen effluvium recovery rates Telogen effluvium from weight loss, including GLP-1 mediated weight loss, is a self-limiting condition
Compounding pharmacies are not required to track, evaluate, or report adverse events to the FDA
Pigment is one path, but it is not the only one
Some individuals may also experience fatigue or mild dizziness in the early stages, which may relate to changes in caloric intake or blood glucose regulation
Belapectin, a galectin-3 inhibitor, was well tolerated in a year-long biweekly infusion but showed no significant effects on hepatic venous pressure gradient (HVPG) or fibrosis in a phase 2B study involving 162 patients with MASH, cirrhosis, and portal hypertension
G.LigiD.OrlandiC.GalluzziL.et al (2016)